🔎 Trials Near Me

Home › Cancro al seno › Oregon › Portland

Studi clinici su Cancro al seno a Portland, OR

33 studi su Cancro al seno cercano partecipanti presso sedi a Portland e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

In reclutamentoFase 3
  • Oregon Health & Science University, Knight Cancer Institute, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT06982521

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

In reclutamentoFase 1/2
  • Oregon Health & Science University (OHSU), Portland
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

In reclutamentoFase 3
  • Northwest Cancer Specialists, Portland
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

In reclutamentoStudio osservazionaleVolontari sani benvenuti
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · a 12 mi di distanza
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

In reclutamentoFase 1/2
  • Compass Oncology - Rose Quarter Cancer Center, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07701941

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

In reclutamentoFase 1
  • Research Site, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05877599

Study of AVZO-021 in Patients With Advanced Solid Tumors

In reclutamentoFase 1/2
  • Avenzo Therapeutics Recruiting Site, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

In reclutamentoFase 3
  • Providence Portland Medical Center ( Site 0044), Portland
  • Providence St. Vincent Medical Center ( Site 0081), Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06312176

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

In reclutamentoFase 2
  • Oregon Health and Science University, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

In reclutamentoFase 1/2
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
  • Local Institution - 0052, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06618287

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

In reclutamentoFase 3
  • Clinical Trial Site, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

In reclutamentoFase 3
  • Oregon Health and Science University, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

In reclutamentoFase 2
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07287098

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

In reclutamentoFase 3
  • Providence Portland Medical Center, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07173751

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

In reclutamentoFase 3
  • Providence Cancer Institute Franz Clinic, Portland
  • Providence Cancer Institute Franz Clinic, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

In reclutamentoFase 1
  • Providence Portland Medical Center, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

In reclutamentoFase 1
  • Providence Cancer Institute, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06253871

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

In reclutamentoFase 3
  • Providence Portland Medical Center, Portland
  • Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

In reclutamentoFase 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Kaiser Permanente Northwest, Portland
  • e altri 2
Età da 18 a 60 · Donne · Aggiornato il 2 set 2026 · NCT05879926

A Study of MGC026 in Participants With Advanced Solid Tumors

In reclutamentoFase 1
  • Providence Cancer Institute, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06242470

E-Mindfulness Approaches for Living After Breast Cancer

In reclutamentoFase 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Kaiser Permanente Northwest, Portland
  • e altri 1
Età da 18 a 50 · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT06748222

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

In reclutamentoFase 1/2
  • Compass Oncology - Rose Quarter, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366

Identifying and Caring for Individuals With Inherited Cancer Syndrome

In reclutamentoVolontari sani benvenuti
  • Providence Portland Medical Center, Portland
  • OHSU Knight Cancer Institute, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 lug 2026 · NCT04494945

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

In reclutamentoFase 1/2
  • Providence Cancer Institute Franz Clinic, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

In reclutamentoFase 2
  • OHSU Knight Cancer Institute, Portland
Età da 18 a 100 · Tutti i sessi · Aggiornato il 5 giu 2026 · NCT04529044

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

In reclutamentoFase 2
  • Oregon Health & Science Institute (OHSU), Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT01042379

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

In reclutamentoFase 3
  • Legacy Good Samaritan Hospital and Medical Center, Portland
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • e altri 1
Età da 50 a 70 · Tutti i sessi · Aggiornato il 23 apr 2026 · NCT04852887

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

In reclutamentoStudio osservazionale
  • Kaiser Permanente Northwest, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

In reclutamentoStudio osservazionaleVolontari sani benvenuti
  • Oregon Health Sciences University, Portland
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

In reclutamentoStudio osservazionale
  • Massive Bio SYNERGY-AI site, Portland
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

In reclutamentoFase 3
  • Kaiser Permanente Northwest, Portland
  • Oregon Health and Science University, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 ott 2025 · NCT03418961

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

In reclutamentoStudio osservazionale
  • Legacy Good Samaritan Medical Center, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2025 · NCT03053193

EMBRACE: Exercising Together

In reclutamentoFase 2Volontari sani benvenuti
  • OHSU Knight Cancer Institute, Portland
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2025 · NCT06049355

Studi su Cancro al seno in altre città

Altri studi a Portland

Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.